NewAmsterdam Takes Another Step Toward CETP Inhibitor Success

 
• By Alaric DeArment
NewAmsterdam announced topline Phase II results for its cholesterol-lowering CETP inhibitor • Source: Shutterstock

More from Clinical Trials

More from R&D